Emergent BioSolutions Inc
For the period ended Dec 31, 2024. Filed Mar 4, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 4, 2025
EBS$6.05-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Index to Consolidated Financial Statements | Page |
|---|---|
| Report of Independent Registered Public Accounting Firm | 91 |
| Consolidated Balance Sheets for the years ended December 31, 2024 and December 31, 2023 | 93 |
| Consolidated Statements of Operations for the years ended December 31, 2024, December 31, 2023 and December 31, 2022 | 94 |
| Consolidated Statements of Comprehensive Loss for the years ended December 31, 2024, December 31, 2023 and December 31, 2022 | 95 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024, December 31, 2023 and December 31, 2022 | 96 |
| Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2024, December 31, 2023 and December 31, 2022 | 97 |
| Notes to Consolidated Financial Statements | 98 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.